Lupus Nephritis

The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.

Health care professionals around the world are reporting that the COVID-19 pandemic has prevented patients with systemic lupus erythematosus from receiving optimal care, resulting in increased risk for organ damage, according to a survey.

PHILADELPHIA — Half of patients with systemic lupus erythematosus and new-onset, low-grade proteinuria progress to clinical proteinuria within 2 years, according to results of a study presented at ACR Convergence 2022.

ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.

In the 4 decades since 1976, the incidence and prevalence of lupus nephritis has increased among the population in Minnesota, according to data published in Arthritis Rheumatology.

SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.

Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.

Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.

Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.